within Pharmacolibrary.Drugs.ATC.B;

model B01AC21_1
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.17,
    Cl             = 0.5483333333333333,
    adminDuration  = 600,
    adminMass      = 0.001,
    adminCount     = 1,
    Vd             = 0.0438,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0019333333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Treprostinil is a stable, synthetic analog of prostacyclin (PGI2) used primarily for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. It acts as a vasodilator of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation. It is approved for use in several countries and can be administered intravenously, subcutaneously, orally, or by inhalation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after oral administration of treprostinil extended-release tablets.</p><h4>References</h4><ol><li><p>Hopper, RK, et al., &amp; Feinstein, JA (2020). Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension. <i>Journal of cardiovascular pharmacology</i> 76(1) 94–100. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0000000000000842&quot;>10.1097/FJC.0000000000000842</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32398473/&quot;>https://pubmed.ncbi.nlm.nih.gov/32398473</a></p></li><li><p>Jones, A, et al., &amp; Laliberte, K (2014). Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. <i>Journal of cardiovascular pharmacology</i> 63(3) 227–232. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0000000000000039&quot;>10.1097/FJC.0000000000000039</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24603117/&quot;>https://pubmed.ncbi.nlm.nih.gov/24603117</a></p></li><li><p>White, RJ, et al., &amp; Tapson, VF (2013). Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension. <i>Journal of cardiovascular pharmacology</i> 61(6) 474–481. DOI:<a href=&quot;https://doi.org/10.1097/FJC.0b013e31828685da&quot;>10.1097/FJC.0b013e31828685da</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23328389/&quot;>https://pubmed.ncbi.nlm.nih.gov/23328389</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC21_1;
